Congenital central hypoventilation syndrome (CCHS, Ondine's curse) is a rare disorder of the chemical control of breathing. It is frequently associated with a broad spectrum of dysautonomic symptoms, suggesting the involvement of genes widely expressed in the autonomic nervous system. In particular, the HASH-1-PHOX2A-PHOX2B developmental cascade was proposed as a candidate pathway because it controls the development of neurons with a definitive or transient noradrenergic phenotype, upstream from the RET receptor tyrosine kinase and tyrosine hydroxylase. We recently showed that PHOX2B is the major CCHS locus, whose mutation accounts for 60% of cases. We also studied the proneural HASH-1 gene and identified a heterozygous nucleotide substitution in three CCHS patients. To analyze the functional consequences of HASH-1 mutations, we developed an in vitro model of noradrenergic differentiation in neuronal progenitors derived from the mouse vagal neural crest, reproducing in vitro the HASH-PHOX-RET pathway. All HASH-1 mutant alleles impaired noradrenergic neuronal development, when overexpressed from adenoviral constructs. Thus, HASH-1 mutations may contribute to the CCHS phenotype in rare cases, consistent with the view that the abnormal chemical control of breathing observed in CCHS patients is due to the impairment of noradrenergic neurons during early steps of brainstem development.
INTRODUCTION
Congenital central hypoventilation syndrome (CCHS, Ondine's curse, MIM 209880) is a life-threatening disorder characterized by persistent hypoventilation during sleep, beginning in the neonatal period and requiring life-long ventilatory assistance (1) . While the pathophysiologic mechanisms underlying CCHS remain elusive, several lines of evidence suggest that genetic factors are involved (occurrence in siblings, concordant monozygotic twins and rare vertical transmission) (2) .
Changes in the integration of afferent inputs from central and peripheral chemoreceptors in the brainstem are the most likely disease mechanisms. In addition, most CCHS patients present a broader defect of the autonomic nervous system (3), including Hirschsprung disease (25-30% of cases, Haddad syndrome, MIM 209880) (2), a malformation of the enteric nervous system that has been ascribed to a mutation at the RET receptor tyrosine kinase locus. In mice, the Ret signaling pathway, which involves the sequential expression of the Mash1, Phox, Ret and TH genes, is responsible for the development of all transient or permanent noradrenergic derivatives (4, 5) . We recently showed that PHOX2B is the major disease-causing gene in both CCHS and Haddad syndromes, with an autosomal dominant mode of inheritance and de novo mutations at the first generation (2) . Cross-regulation of the Phox2 and Mash-1 genes has been shown in mice (6, 7) ; moreover, newborn Mash-1 þ/À heterozygous mice show an impaired ventilatory responses to hypercarbia (8) . We therefore regarded the human ortholog of Mash1 (HASH-1), which encodes a tissue-specific basic helix-loop-helix transcription factor, as an additional candidate gene for CCHS. We identified a heterozygous nucleotide substitution of the HASH-1 gene in three patients. The functional consequences of HASH-1 mutations were studied using a novel in vitro model of noradrenergic differentiation based on neuronal progenitors derived from the mouse vagal neural crest and reproducing in vitro the HASH-PHOX-RET pathway. Forced expression of each of the mutant HASH-1 alleles induced the impairment of noradrenergic neuronal development. We conclude that, at least in some cases, heterozygous HASH-1 mutation may contribute to the CCHS phenotype by modifying noradrenergic neurons during early steps of brainstem development, and that the HASH-1 gene is tightly involved in the formation of the neuronal network for autonomous control of ventilation in human.
RESULTS

HASH-1 heterozygous nucleotide substitutions
We screened the single coding exon of HASH-1 for nucleotide variations in a series of 30 CCHS patients (Fig. 1) . We obtained an abnormal SSCP pattern in three cases. Direct DNA sequencing showed a C to A transversion at nucleotide 52, resulting in a proline to threonine substitution at amino acid position 18 (P18T), in a female patient with isolated CCHS. Two in-frame deletions of five (111-125del15nt, A37-A41del) and eight (108-131del24nt, A36-A43del) alanine codons in a 13-residue polyalanine tract, were identified in female patients with CCHS and Haddad syndrome respectively (Fig. 1A) . Both the P18T and the A37-A41del mutations were inherited from the healthy father (Fig. 1A) , while the mother of the patient with the A36-A43del mutation was not available for study. The HASH-1 mutations are located in regions highly conserved across mammalian ASH genes as shown by Clustal W analysis (Fig. 1B) . These data suggest that these protein domains are functionally relevant. Accordingly, none of the HASH-1 gene mutations was detected in a panel of 120 control chromosomes. Interestingly, a de novo mutation of PHOX2B (polyalanine expansion of seven alanines) was found in the patient harboring the P18T mutation of the HASH-1 gene, whereas direct sequencing of the three exons of PHOX2B showed no variation in the other two cases. Indeed, all CCHS patients described in this series have been tested for the RET, GDNF and PHOX2B genes (2).
HASH-1 expression in early human development
We further investigated the possible involvement of HASH-1 mutations in the CCHS phenotype by studying the pattern of expression of HASH-1 in early human development (Fig. 2) . Consistent with the wide spectrum of afferent nervous system (ANS) dysfunction observed in CCHS patients and the pattern of expression in mice (9, 10) , HASH-1 is expressed in both the central nervous system (mesencephalon, rhombencephalon, spinal cord; Fig. 2A, B and E-H), and the peripheral nervous system (cells lining the dorsal aorta, presumed to be neural crest-derived precursors of the sympathetic ganglia, Fig. 2C and D) from Carnegie stage 14. At Carnegie stage 18, HASH-1 expression was detected in the presumptive enteric nervous system, from the esophagus to the rectum ( Fig. 2E-H ) and in the adrenal medulla ( Fig. 2I and J) .
Functional analysis of HASH-1 mutant alleles
We investigated the effects of the HASH-1 mutated alleles on their transcriptional activity by means of a luciferase assay. P19 cells were co-transfected with HASH-1 alleles (þ/À E47) and the luciferase gene under the control of the Delta1 promoter. The transcriptional activities of the P18T and A36-A43del alleles were similar to that of the control, regardless of whether the E47 cofactor was present (data not shown, available on request).
We then overexpressed the wild-type and mutant HASH-1 alleles, and assessed the functional consequences for the differentiation of the noradrenergic lineage, using the PHOX-RET signaling pathway and the tyrosine hydroxylase (TH) phenotype as markers (11, 12) . We demonstrated that undifferentiated vagal neural crest progenitor cells, isolated from E9 mouse embryos, may be engaged in noradrenergic differentiation, and then sequentially produce Phox2a, Ret, and TH, thereby reproducing the mouse Mash-1 molecular cascade (Fig. 3A) . Interestingly, no alternative lineage was obtained, as almost all THþ cells were derived from PHOX2A-expressing neurons. We then showed that it was possible to reproduce the catecholaminergic differentiation pathway, 72 h after the forced expression of HASH-1 by recombinant adenoviruses (Fig. 3B and C). All the infected cells (100%) were transduced with the HASH-1 adenoviral constructs (Fig. 4) , as shown by GFP production (Fig. 4B) . The overexpression of wild-type HASH-1 resulted in the differentiation of 52.3 AE 3% (n ¼ 12) of neural crest cells into postmitotic noradrenergic derivatives, as shown by Phox2a production (data not shown). These values are similar to those previously reported for retroviral forced expression (11) . We investigated the functional consequences of HASH-1 gene mutations for the noradrenergic lineage (Fig. 4B) . All mutated forms of HASH-1 tested led to a significant decrease (20-30%) in the number of neuronal derivatives of the noradrenergic lineage, as shown by Phox2a production (Fig. 4B) . In particular, only 34.4 AE 0.7% (p < 0.001) of neural crest progenitors differentiated to give a noradrenergic phenotype using the A37-A41del HASH-1 mutant construct, whereas 39.3 AE 0.6% and 38.7 AE 0.6% of cells produced Phox2a when the P18T and A36-A43del HASH-1 mutant alleles, respectively, were used (P < 0.01; Fig. 4B ).
DISCUSSION
Taking advantage of the well-characterized specification of catecholaminergic neurons derived from the vagal neural crest (5), we recapitulated in vitro the molecular cascade involved in the early steps of noradrenergic determination. In that system, we used a forced expression of wild-type and mutant HASH-1 to test the functional relevance of mutated HASH-1 alleles identified in CCHS patients. We showed a significant decrease in the number of noradrenergic neurons generated after expression of mutant HASH-1 alleles. However, this is a limited effect considering that patients are heterozygotes for the HASH-1 mutated allele as opposed to our experimental model. Nevertheless, subtle consequences on the noradrenergic neuronal development could be expected with HASH-1 gene mutations lying outside of the bHLH domain of the protein.
Moreover, the HASH-1 mutations were located in highly conserved regions of the protein, although not involved in the basic helix-loop-helix consensus motives (13) . Together with the expression pattern of HASH-1 in the developing human embryo, these results cope well with the phenotype of heterozygous Mash-1 þ/À mice (10) . These data also suggest that variant HASH-1 alleles may contribute to the CCHS phenotype. However, HASH-1 gene mutations are neither necessary (most patients do not have a HASH-1 gene variant), nor sufficient for CCHS to occur (carriers have no phenotypic expression). This observation is reminiscent of the findings in isolated Hirschsprung disease in the Mennonite population, where endothelin B receptor (EDNRB) mutations are neither necessary nor sufficient for the disease to occur and act in conjunction with a yet unknown hypomorphic RET allele (14) . The question as to whether HASH-1 acts as a modifier of PHOX2B, and/or a disease-causing autosomal dominant gene with incomplete penetrance remains unresolved. Polyalanine repeats are common in transcription factors but their normal function is largely unknown. Expansions of polyalanine tracts in transcription factors, including de novo PHOX2B polyalanine expansions in CCHS, have been shown to be responsible for disease in several malformation syndromes in humans (15, 16) , whereas contractions have not been reported thus far. Polyalanine contractions may therefore act as hypomorphic alleles.
As the CCHS phenotypes of patients with PHOX2B and HASH-1 mutations are undistinguishable, our data suggest that any mutation affecting the HASH-1-PHOX developmental pathway is likely to impair the development of neurons of the D) . HASH-1 expression was also detected in the intestine, from the foregut (arrow, F) to the hindgut (arrow, H), and in the adrenal medulla (arrow, J) at Carnegie stage 18. ad, Adrenal gland; ao, aorta; go, gonad; meta, metanephros; mes, mesencephalon; meso, mesonephros; e, esophagus; re, rectum; rh, rhombencephalon; sc, spinal cord. 
MATERIALS AND METHODS
Patients
A series of 30 patients fulfilled the inclusion criteria for diagnosis of CCHS namely: (i) hypoventilation, hypoxemia and hypercarbia during quiet sleep on polygraphic respiratory recording; with (ii) no cardiac, pulmonary, neuromuscular, EEG or cerebral MRI abnormality (17) . Haddad syndrome was diagnosed in 11 cases (36%, five long segment HSCR, two short segment HSCR, four unknown). The histological criteria for HSCR were: (i) absence of enteric plexuses with histological evaluation of the aganglionic tract; and (ii) strong histochemical staining of acetylcholinesterase in nerve fibers. Blood samples were obtained with informed consent and DNA was extracted according to standard protocols.
We screened the coding sequence of the HASH-1 gene by single-strand conformation polymorphism (SSCP) analysis and/or direct DNA sequencing. The PCR products were heated for 10 min at 95 C, loaded onto a Hydrolink MDE gel (Bioprobe), and subjected to electrophoresis at 4 W. The gel was then dried and placed against a X-ray film for 48 h. If an abnormal SSCP pattern was observed, direct DNA sequencing was performed by the fluorometric method, for both strands (Big DyeTerminator Cycle Sequencing kit, Applied Biosystems, Warrington, UK).
In situ hybridization in human embryos
Human embryos and fetal tissues were collected from legally terminated pregnancies in agreement with French law and ethics committee recommendations. Tissues were prepared as previously described (18) . A 222 bp PCR fragment corresponding to HASH-1 exon 1 was amplified from human genomic DNA with a T7 extension (TAATACGACTCACTAGGGAGA) added to both primers to generate the sense and antisense probes. Probes were labeled with [
35 S]UTP and purified as previously described (2) . Tissues on slides were dehydrated, placed against BIOMAX MR X-ray film (Amersham) for 3 days, and immersed in Kodak NTB2 emulsion for 3 weeks at þ4
C. Developed and toluidine blue-counterstained slides were analyzed with dark-and bright-field illumination. No hybridization signal was detected with the sense probe (data not shown).
Construction of adenoviral plasmids
Adenoviral plasmids were constructed using the Adeasy system (19) . Polyalanine tract contractions and the control HASH-1 coding sequence were amplified by polymerase chain reaction with the 5 0 primer, TCTAGACGCATGGAAA-GCTCTGCCAA, and the 3 0 primer, GTCGACTCAGAACC-AGTTGGTGAAGTCGA, using genomic DNA from controls or patients. PCR-derived fragments were checked by sequencing and subcloned into the pAd-track CMV vector, using the XbaI-SalI restriction sites. PAd-track CMV vectors were used to produce viruses that could be tracked by following GFP fluorescence. Adenoviral plasmids were generated by homologous recombination in electrocompetent E. coli BJ5183, according to the manufacturer's instructions (Stratagene). Adenoviral plasmids were then cut with PacI and viral stocks were produced in QBI-293A cells.
Mouse neural crest culture
Neural crest cells were cultured as previously described (20) . Neural tubes were microdissected from Swiss mouse (Iffa Credo) embryos on day 9 of gestation. Somites and surrounding tissues were removed to obtain neural tube segments corresponding to the first seven somites of the vagal region. These segments were then plated on fibronectin-coated glass coverslips (10 mg/ml, Boehringer Roche) and cultured for 2 days in DMEM (Life Technologies) supplemented with 10% fetal calf serum (AbCys) and 100 IU/ml penicillin/streptomycin (Life Technologies), at 37 C, in a humidified atmosphere containing 5% CO 2 .
Infection of primary cultures of neural crest cells
We tested various levels of multiplicity of infection (MOI) and decided to use 2000 plaque-forming unit (pfu), which gave 100% infected neural crest cells. Neural crest cells (NCCs) were cultured for 2 days, infected on day 2 and fixed 24 h later.
